Tauzin-Fin Patrick, Bernard Olivier, Sesay Musa, Biais Matthieu, Richebe Philippe, Quinart Alice, Revel Philippe, Sztark Francois
Department of Anesthesiology, Bordeaux University Hospital, Place Amélie Raba Léon, Bordeaux cedex, France.
J Anaesthesiol Clin Pharmacol. 2014 Jul;30(3):366-72. doi: 10.4103/0970-9185.137269.
Intravenous (I.V.) lidocaine has analgesic, antihyperalgesic and anti-inflammatory properties and is known to accelerate the return of bowel function after surgery. We evaluated the effects of I.V. lidocaine on pain management and acute rehabilitation protocol after laparoscopic nephrectomy.
A total of 47 patients scheduled to undergo laparoscopic nephrectomy were included in a two-phase observational study where I.V. lidocaine (1.5 mg/kg/h) was introduced, in the second phase, during surgery and for 24 h post-operatively. All patients underwent the same post-operative rehabilitation program. Post-operative pain scores, opioid consumption and extent of hyperalgesia were measured. Time to first flatus and 6 min walking test (6MWT) were recorded.
Patient demographics were similar in the two phases (n = 22 in each group). Lidocaine significantly reduced morphine consumption (median [25-75% interquartile range]; 8.5 mg[4567891011121314151617] vs. 25 mg[1920212223242526272829303132]; P < 0.0001), post-operative pain scores (P < 0.05) and hyperalgesia extent on post-operative day 1-day 2-day 4 (mean ± standard deviation (SD); 1.5 ± 0.9 vs. 4.3 ± 1.2 cm (P < 0.001), 0.6 ± 0.5 vs. 2.8 ± 1.2 cm (P < 0.001) and 0.13 ± 0.3 vs. 1.2 ± 1 cm (P < 0.001), respectively). Time to first flatus (mean ± SD; 29 ± 7 h vs. 48 ± 15 h; P < 0.001) and 6MWT at day 4 (189 ± 50 m vs. 151 ± 53 m; P < 0.001) were significantly enhanced in patients with i.v. lidocaine.
Intravenous (I.V.) lidocaine could reduce post-operative morphine consumption and improve post-operative pain management and post-operative recovery after laparoscopic nephrectomy. I.V. lidocaine could contribute to better post-operative rehabilitation.
静脉注射利多卡因具有镇痛、抗痛觉过敏和抗炎特性,且已知其可加速术后肠功能恢复。我们评估了静脉注射利多卡因对腹腔镜肾切除术后疼痛管理和急性康复方案的影响。
共有47例计划接受腹腔镜肾切除术的患者纳入一项两阶段观察性研究,在第二阶段,于手术期间及术后24小时静脉注射利多卡因(1.5毫克/千克/小时)。所有患者均接受相同的术后康复方案。测量术后疼痛评分、阿片类药物消耗量和痛觉过敏程度。记录首次排气时间和6分钟步行试验(6MWT)结果。
两个阶段的患者人口统计学特征相似(每组n = 22)。利多卡因显著减少吗啡消耗量(中位数[25 - 75%四分位数间距];8.5毫克[4567891011121314151617] 对比 25毫克[1920212223242526272829303132];P < 0.0001)、术后疼痛评分(P < 0.05)以及术后第1天、第2天和第4天的痛觉过敏程度(均值 ± 标准差(SD);1.5 ± 0.9厘米对比4.3 ± 1.2厘米(P < 0.001)、0.6 ± 0.5厘米对比2.8 ± 1.2厘米(P < 0.001)和0.13 ± 0.3厘米对比1.2 ± 1厘米(P < 0.001))。静脉注射利多卡因的患者首次排气时间(均值 ± SD;29 ± 7小时对比48 ± 15小时;P < 0.001)和第4天的6MWT(189 ± 50米对比151 ± 53米;P < 0.001)显著改善。
静脉注射利多卡因可减少腹腔镜肾切除术后的吗啡消耗量,改善术后疼痛管理和术后恢复。静脉注射利多卡因有助于更好地进行术后康复。